CVS to Cover Lilly’s GLP-1 Medications, Expanding Access
CVS Health will broaden coverage for Lilly’s GLP-1 medications, including the new pill Foundayo and Zepbound injectio...
A quick guide to reputable sources for index level data, plus tips on choosing datasets and validating their reliability for analysis.
24,978 articlesCVS Health will broaden coverage for Lilly’s GLP-1 medications, including the new pill Foundayo and Zepbound injectio...
When the next earnings season looms, a single well-chosen tech stock can outshine a broad, aimless portfolio. Learn h...
As the next market cycle approaches, traders are weighing XRP against Hyperliquid, weighing price action, liquidity, ...
Investors are watching Bionano Genomics as the company enters 2026 with evolving demand for optical genome mapping. T...
Investors are eyeing Lilly for its resilient growth, strong pipeline, and shareholder-friendly strategy. This piece b...
Rivian stock moved higher this week without a formal press release, boosted by direct investor outreach and renewed i...
XRP has clawed back from a fresh 19-month low, trading near $1.13 after a sharp drop to $1.05. Analysts warn the path...
Kris Zacuto has joined Christie’s International Real Estate Southern California as director of luxury estates, bringi...
As UNFI approaches its 2026 earnings call, investors want clarity on margins, growth drivers, and capital strategy. T...
SpaceX's much-anticipated IPO is expected to deliver a first-day surge that could surpass historic records. Valued ar...
Plans for a UFC event on the White House grounds feature a towering, temporary arena dubbed the Claw Cage. As costs r...
Lam Research surged about 21% from its June trough as markets priced in a slower path for rate hikes. This report wei...